Navigation Links
74 Percent EBITDA Improvement at Zeltia Group in 2010
Date:2/24/2011

MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova an
'/>"/>

SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. 34 percent of Galician secondary schools exceed maximum recommended radon levels
2. 34 percent of Galician secondary schools exceed maximum recommended radon levels
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. ReVisions Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
5. Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent
6. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
7. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
8. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 IMS is ... bring it to the web and provide greater ... user friendly reporting metrics increase data warehouse’s utility; ... convenient recall and access “on-the-go” makes data analysis ... using client feedback to assist in repository analytics ...
(Date:4/28/2015)... Reproductive endocrinologist Dr. Kaylen Silverberg , ... battling infertility in this country, testified on behalf of ... first state in the nation to consider creating a clearinghouse ... who desire to receive them. , Infertility affects over 7.3 ... is one of the few medical diseases that is curable, ...
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... Kan. , April 27, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today provided commentary on clinical study ... during a poster session at the American Association ... ADXS31-164 is a novel Lm -LLO ...
Breaking Biology Technology:Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... the Southern District of New York dismissed proceedings filed ... ("Axonyx") against Axonyx and several of Axonyx,s former directors ... plaintiffs alleged that the defendants made misleading statements related ...
... Enterprises, Inc. (BME), a rapidly growing medical device company ... implants, announced today that it has appointed Keith M. ... BME specializes in nitinol implants that contract and compress ... bone union. The O rthopaedic S ...
... Cell Trial to Show Dose-related Significant Improvement in Perfusion ... Amorcyte, Inc. (Amorcyte) today announced data from its Phase ... for the treatment of damaged heart muscle following acute ... cell dose and biologic effect. This is the first ...
Cached Biology Technology:Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed 2BioMedical Enterprises, Inc. (BME) Announces the Appointment of Keith M. Peeples as Vice President, Sales and Marketing 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 2Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 3Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session 4
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
... Streptavidin-Horseradish Peroxidase Conjugate, 2 ... reporter enzyme molecules for ... in situ hybridization applications.High ... & Labeling & Detection, ...
...
normal rat IgM AF647...
Chicken anti-EEA1...
Biology Products: